Skip to content

The Study of Clinical Efficacy and Safety of Benjakul Remedy in Stage 4 Non Small Cell Lung Cancer

The Study of Clinical Efficacy and Safety of Benjakul Remedy in Stage 4 Non Small Cell Lung Cancer

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20150805001
Enrollment
16
Registered
2015-08-05
Start date
2014-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosed with non&#45

Interventions

Benjakul recipe capsule at dose of 100 mg. Take 2 capsules 3 times a day (600 mg /day) is for 24 weeks
Experimental Drug

Sponsors

National research council of thailand
Lead Sponsor
Assoc.Prof.Dr. Arunporn Itharat
Collaborator

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Females and males aged 25-70 years 2. Diagnosed with non-small cell lung cancer stage 4, confirmed by pathology and radiology 3. Do not respond to chemotherapy at least two formulas and can not be treated with drugs targetted. 4. Have never used herbs in the treatment of non-small cell lung cancer. 5. ECOG (Eastern Cooperative Oncology Group) performance status performance patients based on a scale of 0 to 2A 6. The following laboratory criteria 6.1 Hemoglobin ≥ 10 grams per deciliter 6.2 Leukocytes ≥ 3.0 x 109 / L 6.3 Lymphocyte Type of neutrophils > 1.5 x 109 / L 6.4 Platelet > 75 x 109 / L 6.5 Aspartate transferase (AST), alanine aminotransferase (ALT), alkaline phosphatase(ALP), bilirubin no more than 3 times that of standard 6.6 Creatinine no more than 1.5 mg per deciliter 7. Patients treated and followed up on schedule. 8. Volunteers must make a conscious decision to participate in the research themselves. 9. Patient understands and signs consent to participate in research.

Exclusion criteria

Exclusion criteria: 1. ECOG Performance status in range the 3 to 5 2. The disease has spread to the brain 3. Has herbal drug allergy 4. Are pregnant or breastfeeding 5. Taking chemotherapy or other herbs during the study 6. Take medicine regularly for peptic ulcer 7. People who have problems swallowing who can not eat the capsule 8. Are participating in other research programs

Design outcomes

Primary

MeasureTime frame
progression free survival ,time to tumor progression 8 month Radiology test

Secondary

MeasureTime frame
quality of life 8 month Thai-Modified Function Living Index Cancer Questionnaire (T-FLIC version 2 )

Countries

thailand

Contacts

Public ContactHataiwan Ratanabunjerdkul

Faculty of medicine

hataiwan_r@hotmail.com0-2926-9793

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026